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ABSTRACT
Population aging is a reality that is being faced 
worldwide, and Brazil is no different. Osteoporosis was 
considered to be a postmenopausal women’s disease for 
many years. Men have many development and hormonal 
factors that differentiate their skeletal maturation, which 
affects the incidence of osteoporosis and fractures. An 
up-to-date review of the specific literature within the 
Medline system is presented.
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INTRODUCTION
Osteoporosis was for a long time considered to be 
a women’s disease. Today, it is being recognized that 
osteoporosis is also a public health issue for men, given 
the significance incidence of osteoporotic fractures that 
they present(1). 
Postmenopausal osteoporosis is a characteristic of 
hormone loss, i.e. of estrogen in postmenopausal wom-
en. In men, testosterone levels remain functional until 
the seventh decade of life. For this reason, it was thought 
that men would not have osteoporosis and would not 
need hormone replacement. The existence of risk factors 
within modern life and the aging of the population have 
brought male osteoporosis into view.
Definition, risk factors and classification
Osteoporosis is a systemic disease of the skeleton 
characterized by compromised bone resistance that 
predisposes towards an increased risk of fractures. Hip 
fractures are the most severe of these, and they occur 
at later stages of life(2). Bone resistance is provided by 
the combination of bone mass (as assessed using den-
sitometry) and bone quality (in terms of bone macro 
and microarchitecture and metabolic activity), with 
their interactions with local and systemic factors. Sex-
ual hormones, systemic bone metabolism factors and, 
especially, testosterone in men have important roles in 
determining the bone mass(3). Bone densitometry pro-
vides measurements of bone mineral density (BMD), 
and this directly assesses the bone mineral content. 
There has been much discussion regarding whether the 
fracture risk gradient, according to BMD values, differs 
between men and women(4). From an analysis on 12 
cohorts, Johnell et al(5) concluded that the risk of hip 
fractures according to age and BMD among men was 
similar to that of women of the same age and BMD(5). 
They found that the incidence of fractures and mortal-
ity among women at more advanced ages was greater 
than among men because of women’s greater longevity, 
and they also concluded that hip BMD values were an 
important risk factor for fractures, independent of sex(5). 
In Brazil, through statistics from the Brazilian Institute 
for Geography and Statistics (IBGE), it can be seen that 
the population is aging. For example, the population 
pyramid has become inverted, comparing the male and 
female populations over the age of 80 years for 1980 
with the projection for 2050 (Figure 1). The Brazilian 
population over the age of 50 years is remaining very 
active and is increasing in numbers, thereby leading to 
increased incidence of the diseases that progress with 
aging, notably osteoporosis.
A variety of factors contribute towards the fact that 
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women are affected more than men are: men attain a 
higher peak bone mass than women do and do not have 
the losses consequent to the menopause(6). Different pat-
terns of bone loss over the course of time contribute 
towards a biomechanical advantage with aging. Histo-
ries of fracture due to mild trauma are an important risk 
factor for the occurrence of new fractures, and such pa-
tients are candidates for treatment after they have been 
correctly diagnosed with osteoporosis. The treatment 
consists of calcium supplementation and administration 
of the most appropriate medication(7).
Male osteoporosis is classified as primary or second-
ary. Primary osteoporosis may be idiopathic or because 
of aging, and this form is also called senile osteoporosis 
in both sexes.
In diagnosing male osteoporosis, it is important to 
investigate the risk factors. Kanis et al(8) validated risk 
factors in several cohorts and created models integrated 
with BMD to predict the risk of fractures. The most 
important of these risk factors, both for men and for 
women are low body mass index (BMI), body BMD, 
family history, use of glucocorticoids, previous fractures, 
smoking, alcohol use and rheumatoid arthritis(8). Senile 
or primary osteoporosis in men tends to occur over the 
age of 70 years, through a combination of factors: di-
minished calcium absorption in the intestine, reduced 
vitamin D activation, diminished osteoblast lifetime and 
lowered sexual hormone levels(9,10). 
Secondary osteoporosis
Causes of osteoporosis can be identified in around 
40% to 60% of men, especially those with osteoporotic 
fractures(11,12). The commonest causes are hypogonadism 
and prolonged corticoid therapy, followed by gastroin-
testinal diseases, vitamin D deficiency, alcoholism and 
chronic use of anticonvulsants, which also appear in 
significant proportions(10). Corticoids induce bone loss 
directly, and indirectly through hypogonadism, through 
suppression of the secretion of hypothalamic gonado-
tropic hormone and the direct effect of diminished tes-
ticular production of testosterone(10). Men using corti-
coids are at increased risk of vertebral and non-vertebral 
fractures(10-12). Androgens influence the proliferation of 
osteoblasts and the production of cytokines, growth fac-
tors and bone matrix proteins, through the androgen re-
ceptors of osteoblasts(13). Hypogonadism before puberty 
has a notable effect on the development of the cortical 
skeleton, which can be alleviated with testosterone(13).
MALE OSTEOPOROSIS




















Figure 1 – Population projection*.
*http://www.1.ibge.gov.br/home/estatistica/população/projecao_da_populacao/piramide/piramide.shtm
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In adults, it leads to diminished metabolism, bone forma-
tion and vitamin D levels, and can be reversed through 
adequate hormone replacement(13).
Although there have been reports that moderate alco-
hol consumption may be associated with gains in bone 
mass, particularly in the great trochanter(13), many stud-
ies have demonstrated that excessive alcohol consump-
tion is associated with osteoporosis and increased risk 
of fractures(13). Stopping the addiction results in gains 
in bone mineral density, and this was demonstrated in 
a study on 30 men who presented a gain of 3%, two 
years after stopping their alcoholism(12,13). The use of 
immunosuppressants during organ transplantation is 
an important factor for triggering osteoporosis, and 
this has been seen in relation to heart, kidney and liver 
transplantation(13). The cause of osteoporosis in men is 
commonly heterogenous, and there may be several fac-
tors contributing towards the existence of the disease. 
Underlying diseases and risk factors should always be 
investigated in the clinical assessment, as indicated in 
Table 1. 
Epidemiology
Fractures occur frequently among men. Fractures 
in men resulting from osteoporosis are a public health 
problem. Hip fractures are the most important type, and 
these present high morbidity and mortality(14), with the 
highest medical costs relating to osteoporosis.
In the United States in 1995, the expenditure on 
osteoporotic fractures was estimated to be US$ 13.8 
billion. Since the worldwide population is aging, it is 
expected that there will be around 6.3 million hip frac-
tures annually by around 2050(14). In the United States, 
the risk of hip fractures over women’s lifespan beyond 
the age of 50 years is around 17.5%, while for men, the 
risk is 6%(14). The risk of spinal fracture is 5% for men 
and 16% for women(13).
Physiopathology
Sexual hormones are responsible for the maturation 
and sexual dimorphism of the skeleton. Boys have an ad-
ditional two years of prepubertal growth because of their 
later puberty, at the age of 14 years. Puberty among girls 
is earlier, at the age of 12 years. The pubertal growth 
spurt among boys lasts for four years, while it lasts for 
three years among girls(15). Thus, males reach a height 
that is 10% greater than seen among females, and a peak 
bone mass that is 25% greater(15). Some of the testoster-
one is transformed into estrogens, which are responsible 
for closure of the epiphyses at the end of the growth 
stage. Aromatase deficiency causes deficient skeletal 
growth, and this is reversible through estrogen therapy 
for men(15,16). Men and women lose similar quantities 
of trabecular bone during the aging process; however, 
thinning of the trabeculae predominates in men, while 
loss of connectivity predominates in women. The resis-
tance of the vertebrae diminishes more through loss of 
connectivity than through thinning of the trabeculae(17). 
Loss of connectivity results from accelerated bone loss, 
with the estrogen deficiency of the menopause(15,17). In 
patients undergoing treatment for prostate cancer with 
androgen inhibitors, the treatment results in a fall in 
bone densitometry values due to the fall in testosterone 
values(18). The importance of sexual hormones in men 
has been established with regard to gaining and main-
taining bone mass, but there is no well-defined correla-
tion in relation to testosterone and fracture rates in cases 
of primary osteoporosis(19).
Adequate calcium intake in the diet and maintenance 
of constant adequate physical activity are important for 
maintaining quality of life during the aging process(20).
DIAGNOSIS
The best means for diagnosing osteoporosis is clini-
cal, with correct assessment of the underlying diseases 
Table 1 – Causes of male osteoporosis and risk factors for os-
teoporosis and osteoporotic fractures, adapted from references 
5, 9, 10, 11 e 12.
Causes of male osteoporosis Risk factors  
● Corticoid use ● Age ≥ 70 years
● Immunosuppressant use
● Fractures before the age of 40 
years
● Hypogonadism ● Maternal history of fractures
● Alcoholism ● Low body mass index
● Smoking ● Low calcium intake
● Chronic obstructive pulmonary 
disease
● Unstable balance 
● Cystic fibrosis ● Quadriceps weakness
● Anticonvulsant medication ● Falls over the last 12 months
● Gastrointestinal diseases ● Caucasian ethnicity
● Ankylosing spondylitis ● Poor visual acuity
● Thyrotoxicosis ● Lumbar pain 
● Hyperparathyroidism ● Sedentarism
● Rheumatoid arthritis ● Use of androgen inhibitors
● Idiopathic hypercalciuria
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that may cause secondary osteoporosis, and the risk fac-
tors, as laid out in Table 1. BMD is as effective among 
men as it is among women for predicting fractures in 
situations of low BMD(21,22). Because of the lower inci-
dence of fractures in men, bone densitometry examina-
tions are requested less often for men than for women.
BMD evaluations should be requested for the following:
• Men aged 50 years and over who suffer fractures 
caused by mild trauma, including those with spinal 
deformities; younger men with fractures due to mild 
trauma should be included in this.
• Men presenting conditions that are known to cause 
secondary osteoporosis, such as hypogonadism, corti-
coid use, alcoholism and other diseases and risk factors, 
as shown in Table 1.
• BMD should be measured routinely among men aged 
70 years and over(23).
Currently, BMD values are quantified as T scores, 
which provide a relationship with the mean peak value 
for skeletal maturation, using a grading system parallel 
to the one used for women: T scores from –1 to –2.5 
signify “low bone mass”, which was previously called 
osteopenia(5); T scores less than or equal to –2.5 signify 
densitometric osteoporosis. The scale for men (male val-
ues) should always be used; there are no adjustments for 
ethnicity. These values are valid for bone densitometry 
examinations performed on apparatus for dual-energy 
x-ray absorptiometry (DXA). Z score values provide a 
relationship with the mean BMD for the age group, less 
than or equal to –2, and a cause for secondary osteopo-
rosis should always be investigated(1,2,22,23). Laboratory 
tests are indicated for evaluating diseases and causes 
of secondary osteoporosis, which should be corrected 
when detected. Box 1 provides a suggestion for a rou-
tine that can be increased or diminished according to 
clinical needs.
In addition to these examinations, biological markers 
for bone metabolism, reabsorption and formation can 
be used, according to the local facilities available for 
medical laboratory services, as shown in Box 2.
Calcium metabolism should be assessed with regard 
to situations of hypo and hypercalcemia. Electrophoresis 
on serum proteins among patients over 50 years of age 
is important particularly for the diagnosis of multiple 
myeloma. Bone scintigraphy should not be a routine ex-
amination, and should just be used in cases of suspected 
bone neoplasia, metastasis or Paget’s disease.
Box 2 – Biochemical markers for bone metabolism(1).
Marcadores bioquimicos do metabolismo ósseo
























The treatment should start with elimination of risk 
factors that can be removed, such as smoking, alco-
hol use and sedentarism. The calcium intake in the diet 
should be brought to adequate levels and physical ac-
tivity advice should be given(20). Treatments for dis-
eases that could be causes of secondary osteoporosis 
should be updated. Corticoid use should be withdrawn 
or adjusted in consultation with the attending physician, 
to the lowest dose possible. Vitamin D levels should 
be evaluated and corrected to normal values, through 
supplementation.
Use of testosterone in men with hypogonadism has 
shown beneficial effects regarding increased BMD 
in the lumbar spine, but the side effects need to be 
evaluated(13). Indications for testosterone use should be 
preceded by an evaluation by a urologist.
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The medications of choice for treating male osteo-
porosis are bisphosphonates, especially alendronate and 
risedronate, which also act on osteoporosis induced by 
corticoids(13,24). Ibandronate(25) and annual intrave-
nous zolendronate may be used. Although strontium 
ranelate has bone-forming properties, no protocol for 
use in men has yet been defined.
Teriparatide is effective in cases of severe osteopo-
rosis with fractures, and also in cases of osteoporosis 
induced by corticoids(2,13).
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